adenine has been researched along with gsk2245035 in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ambery, C; Biggadike, K; Garthside, S; Powley, W; Price, M; Quint, D; Tsitoura, D | 1 |
| Ahmed, M; Ball, DI; Biggadike, K; Coe, DM; Dalmas Wilk, DA; Edwards, CD; Gibbon, BH; Hardy, CJ; Hermitage, SA; Hessey, JO; Hillegas, AE; Hughes, SC; Lazarides, L; Lewell, XQ; Lucas, A; Mallett, DN; Price, MA; Priest, FM; Quint, DJ; Shah, P; Sitaram, A; Smith, SA; Stocker, R; Trivedi, NA; Tsitoura, DC; Weller, V | 1 |
| Ellis, AK; Lee, LA; Powley, W; Quint, D; Tsitoura, DC | 1 |
| Hohlfeld, JM; Lee, L; Pandya, H; Powley, W; Quint, D; Shabbir, S; Siddall, H; Singh, D | 1 |
| Baker, A; Bray, M; Hillegas, AE; Maier, CC; Phadnis-Moghe, AS; Posobiec, LM; Price, MA; Stanislaus, DJ | 1 |
3 trial(s) available for adenine and gsk2245035
| Article | Year |
|---|---|
Early clinical evaluation of the intranasal TLR7 agonist GSK2245035: Use of translational biomarkers to guide dosing and confirm target engagement.
Topics: Adenine; Administration, Intranasal; Adolescent; Adult; Animals; Anti-Allergic Agents; Biomarkers; Chemokine CXCL10; Double-Blind Method; Drug Administration Schedule; Female; Humans; Macaca fascicularis; Male; Middle Aged; No-Observed-Adverse-Effect Level; Piperidines; Rhinitis, Allergic; Risk Assessment; Toll-Like Receptor 7; Treatment Outcome; Young Adult | 2015 |
Safety and pharmacodynamics of intranasal GSK2245035, a TLR7 agonist for allergic rhinitis: A randomized trial.
Topics: Adenine; Administration, Intranasal; Adult; Aged; Allergens; Biomarkers; Drug Monitoring; Female; Follow-Up Studies; Humans; Immunization; Male; Middle Aged; Piperidines; Rhinitis, Allergic; Rhinitis, Allergic, Seasonal; Seasons; Toll-Like Receptor 7; Treatment Outcome; Young Adult | 2017 |
Intranasal GSK2245035, a Toll-like receptor 7 agonist, does not attenuate the allergen-induced asthmatic response in a randomized, double-blind, placebo-controlled experimental medicine study.
Topics: Adenine; Administration, Intranasal; Adult; Allergens; Anti-Asthmatic Agents; Asthma; Bronchial Provocation Tests; Double-Blind Method; Female; Forced Expiratory Volume; Humans; Interferon-alpha; Male; Middle Aged; Piperidines; Proof of Concept Study; Rhinitis, Allergic; Toll-Like Receptor 7; Young Adult | 2020 |
2 other study(ies) available for adenine and gsk2245035
| Article | Year |
|---|---|
Discovery of 6-Amino-2-{[(1S)-1-methylbutyl]oxy}-9-[5-(1-piperidinyl)pentyl]-7,9-dihydro-8H-purin-8-one (GSK2245035), a Highly Potent and Selective Intranasal Toll-Like Receptor 7 Agonist for the Treatment of Asthma.
Topics: Adenine; Administration, Intranasal; Asthma; Dose-Response Relationship, Drug; Drug Discovery; Humans; Molecular Structure; Piperidines; Structure-Activity Relationship; Toll-Like Receptor 7 | 2016 |
GSK2245035, a TLR7 agonist, Does Not Increase Pregnancy Loss in Cynomolgus Monkeys.
Topics: Abortion, Spontaneous; Adenine; Administration, Intranasal; Animals; Asthma; Chemokine CXCL10; Disease Models, Animal; Female; Humans; Interferon-alpha; Macaca fascicularis; Piperidines; Pregnancy; Pregnancy Complications; Toll-Like Receptor 7 | 2021 |